We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+1.61%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$453M
AUM Growth
-$11.2M
Cap. Flow
+$610K
Cap. Flow %
0.13%
Top 10 Hldgs %
80.58%
Holding
26
New
2
Increased
2
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$13.7M
2
PACB icon
Pacific Biosciences
PACB
+$4.87M
3
IMMU
Immunomedics Inc
IMMU
+$3.55M
4
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$1.71M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$4.19M
2
BPMC
Blueprint Medicines
BPMC
+$3.48M
3
AKAO
Achaogen Inc
AKAO
+$3.02M
4
AIMT
Aimmune Therapeutics
AIMT
+$1.41M
5
XLRN
Acceleron Pharma
XLRN
+$1.37M

Sector Composition

Rank Sector Weight
1 Healthcare 57.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
26
PUT
DELISTED
Immunomedics Inc
IMMU
– –
-150,000
Closed -$3.55M
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q3 2018 Portfolio in Review

As of Q3 2018, Foresite Capital Management III held 26 positions worth $453M, down 2.4% from $464M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Foresite Capital Management III's Q3 2018 filing shows 2 new, 2 increased, 9 reduced and 2 closed positions. Its largest new stake was Replimune Group: 779,656 shares worth $12.6M. The largest sale was Solid Biosciences, an estimated $4.19M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 50% a quarter earlier.

  • Foresite Capital Management III's largest Q3 2018 buy was Replimune Group: 779,656 shares worth $12.6M.
  • Foresite Capital Management III added most to Immunomedics Inc in Q3 2018, an estimated $3.55M increase.
  • Foresite Capital Management III's biggest Q3 2018 reduction was Solid Biosciences, cutting an estimated $4.19M.
  • Foresite Capital Management III's ten largest holdings make up 81% of its $453M portfolio in Q3 2018.
  • Foresite Capital Management III opened 2 new positions and closed 2 in Q3 2018.
  • Foresite Capital Management III's portfolio value fell 2.4% quarter-over-quarter to $453M.

Based on Foresite Capital Management III's 13F filing for Q3 2018, filed 13 Nov 2018.